381 related articles for article (PubMed ID: 28674980)
1. The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.
Tippett LJ; Waldvogel HJ; Snell RG; Vonsattel JP; Young AB; Faull RLM
Adv Neurobiol; 2017; 15():129-161. PubMed ID: 28674980
[TBL] [Abstract][Full Text] [Related]
2. Selective neurodegeneration, neuropathology and symptom profiles in Huntington's disease.
Waldvogel HJ; Thu D; Hogg V; Tippett L; Faull RL
Adv Exp Med Biol; 2012; 769():141-52. PubMed ID: 23560309
[TBL] [Abstract][Full Text] [Related]
3. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
[TBL] [Abstract][Full Text] [Related]
4. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
5. Striosomes and mood dysfunction in Huntington's disease.
Tippett LJ; Waldvogel HJ; Thomas SJ; Hogg VM; van Roon-Mom W; Synek BJ; Graybiel AM; Faull RL
Brain; 2007 Jan; 130(Pt 1):206-21. PubMed ID: 17040921
[TBL] [Abstract][Full Text] [Related]
6. Targeting mutant huntingtin for the development of disease-modifying therapy.
Appl T; Kaltenbach L; Lo DC; Terstappen GC
Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
8. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load.
Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
Eur J Neurol; 2008 Nov; 15(11):1180-90. PubMed ID: 18754766
[TBL] [Abstract][Full Text] [Related]
9. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.
Petrella LI; Castelhano JM; Ribeiro M; Sereno JV; Gonçalves SI; Laço MN; Hayden MR; Rego AC; Castelo-Branco M
Hum Mol Genet; 2018 Jun; 27(12):2125-2137. PubMed ID: 29668904
[TBL] [Abstract][Full Text] [Related]
10. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
Nithianantharajah J; Hannan AJ
Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.
Harris AS; Denovan-Wright EM; Hamilton LC; Robertson HA
J Psychiatry Neurosci; 2001 Mar; 26(2):117-22. PubMed ID: 11291528
[TBL] [Abstract][Full Text] [Related]
13. Cortical neurodevelopment in pre-manifest Huntington's disease.
Kubera KM; Schmitgen MM; Hirjak D; Wolf RC; Orth M
Neuroimage Clin; 2019; 23():101913. PubMed ID: 31491822
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Huntington's Disease.
Ghosh R; Tabrizi SJ
Adv Exp Med Biol; 2018; 1049():1-28. PubMed ID: 29427096
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
Flament J; Hantraye P; Valette J
Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional striatal dopamine signaling in Huntington's disease.
Koch ET; Raymond LA
J Neurosci Res; 2019 Dec; 97(12):1636-1654. PubMed ID: 31304622
[TBL] [Abstract][Full Text] [Related]
17. [Huntington's disease: cellular and molecular basis of pathology].
Korzhova VV; Artamonov DN; Vlasova OL; Bezprozvannyĭ IB
Zh Vyssh Nerv Deiat Im I P Pavlova; 2014; 64(4):359-75. PubMed ID: 25723022
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.
Giralt A; Saavedra A; Alberch J; Pérez-Navarro E
J Huntingtons Dis; 2012; 1(2):155-73. PubMed ID: 25063329
[TBL] [Abstract][Full Text] [Related]
19. Expression of the mutant allele of IT-15 (the HD gene) in striatum and cortex of Huntington's disease patients.
Stine OC; Li SH; Pleasant N; Wagster MV; Hedreen JC; Ross CA
Hum Mol Genet; 1995 Jan; 4(1):15-8. PubMed ID: 7711729
[TBL] [Abstract][Full Text] [Related]
20. A modifier of Huntington's disease onset at the MLH1 locus.
Lee JM; Chao MJ; Harold D; Abu Elneel K; Gillis T; Holmans P; Jones L; Orth M; Myers RH; Kwak S; Wheeler VC; MacDonald ME; Gusella JF
Hum Mol Genet; 2017 Oct; 26(19):3859-3867. PubMed ID: 28934397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
